230 related articles for article (PubMed ID: 32876799)
1. Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits.
Bussing D; K Shah D
J Pharmacokinet Pharmacodyn; 2020 Dec; 47(6):597-612. PubMed ID: 32876799
[TBL] [Abstract][Full Text] [Related]
2. Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies.
Naware S; Bussing D; Shah DK
J Pharmacokinet Pharmacodyn; 2023 Aug; ():. PubMed ID: 37558929
[TBL] [Abstract][Full Text] [Related]
3. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
4. A translational platform PBPK model for antibody disposition in the brain.
Chang HY; Wu S; Meno-Tetang G; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):319-338. PubMed ID: 31115858
[TBL] [Abstract][Full Text] [Related]
5. Design and Pharmacokinetic Characterization of Novel Antibody Formats for Ocular Therapeutics.
Gadkar K; Pastuskovas CV; Le Couter JE; Elliott JM; Zhang J; Lee CV; Sanowar S; Fuh G; Kim HS; Lombana TN; Spiess C; Nakamura M; Hass P; Shatz W; Meng YG; Scheer JM
Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5390-400. PubMed ID: 26275136
[TBL] [Abstract][Full Text] [Related]
6. Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches.
Eigenmann MJ; Karlsen TV; Krippendorff BF; Tenstad O; Fronton L; Otteneder MB; Wiig H
J Physiol; 2017 Dec; 595(24):7311-7330. PubMed ID: 28960303
[TBL] [Abstract][Full Text] [Related]
7. Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics.
Li Z; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):305-318. PubMed ID: 31028591
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacokinetics of a recombinant humanized rabbit anti-VEGF monoclonal antibody in rabbits and monkeys.
Yu DA; You M; Ji WW; Lu Y; Liu B; Yan SS
Toxicol Lett; 2018 Aug; 292():73-77. PubMed ID: 29709424
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in The Mouse Eye Following Intravitreal Administration.
Bussing D; Li Y; Guo L; Verma A; Sullivan JM; Shah DK
J Pharm Sci; 2023 Aug; 112(8):2276-2284. PubMed ID: 37062415
[TBL] [Abstract][Full Text] [Related]
10. Ocular tissue distribution and pharmacokinetic study of a small 13kDa domain antibody after intravitreal, subconjuctival and eye drop administration in rabbits.
Gough G; Szapacs M; Shah T; Clements P; Struble C; Wilson R
Exp Eye Res; 2018 Feb; 167():14-17. PubMed ID: 29074387
[TBL] [Abstract][Full Text] [Related]
11. Physiologically Based Pharmacokinetic Model to Support Ophthalmic Suspension Product Development.
Le Merdy M; Tan ML; Babiskin A; Zhao L
AAPS J; 2020 Jan; 22(2):26. PubMed ID: 31907674
[TBL] [Abstract][Full Text] [Related]
12. Ocular Pharmacokinetics of Therapeutic Antibodies Given by Intravitreal Injection: Estimation of Retinal Permeabilities Using a 3-Compartment Semi-Mechanistic Model.
Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Gadkar K; Mazer NA
Mol Pharm; 2017 Aug; 14(8):2690-2696. PubMed ID: 28631484
[TBL] [Abstract][Full Text] [Related]
13. PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data.
Wu S; Le Prieult F; Phipps CJ; Mezler M; Shah DK
J Pharmacokinet Pharmacodyn; 2022 Dec; 49(6):579-592. PubMed ID: 36088452
[TBL] [Abstract][Full Text] [Related]
14. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
Glassman PM; Chen Y; Balthasar JP
J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
[TBL] [Abstract][Full Text] [Related]
15. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model.
Varkhede N; Forrest ML
J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390
[TBL] [Abstract][Full Text] [Related]
16. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
17. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA
Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925
[TBL] [Abstract][Full Text] [Related]
18. Preclinical challenges for developing long acting intravitreal medicines.
Awwad S; Henein C; Ibeanu N; Khaw PT; Brocchini S
Eur J Pharm Biopharm; 2020 Aug; 153():130-149. PubMed ID: 32445965
[TBL] [Abstract][Full Text] [Related]
19. Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents.
Pan X; Stader F; Abduljalil K; Gill KL; Johnson TN; Gardner I; Jamei M
AAPS J; 2020 May; 22(4):76. PubMed ID: 32449129
[TBL] [Abstract][Full Text] [Related]
20. Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system.
Chang HY; Wu S; Chowdhury EA; Shah DK
J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):337-362. PubMed ID: 35092540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
